Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28222954 | 0.85 | HTR2A (0.53) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| SCHEMBL6339887 | 0.85 | HTR1A (0.55) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| Hydrochloric Acid SCHEMBL29960409 | 0.83 | HTR2C (0.54) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| SCHEMBL29960467 | 0.81 | ITGB2 (0.41) | CYP2D6SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL4223377 | 0.81 | ITGB2 (0.41) | CYP2D6SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL2316931 | 0.80 | LTB4R (0.47) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| SCHEMBL2316932 | 0.80 | LTB4R (0.47) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| SCHEMBL6099078 | 0.80 | LTB4R (0.47) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| SCHEMBL2688677 | 0.80 | LTB4R (0.44) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 | |
| SCHEMBL19574896 | 0.80 | LTB4R (0.44) | CYP2D6SLC6A2SLC6A4LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7109265-A | — | — | None | — | — | JP | disclosed |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | SANOFI (FR) | 2024-04-18 | — | — | US | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| CN-108047142-B | Heteroaryl compounds and uses thereof | 西建卡尔有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| JP-H07109265-A | 2,3-DIHYDROBENZOFURAN DERIVATIVE | ASAHI CHEM IND CO LTD | 1995-04-25 | — | — | JP | disclosed |
| US-4751230-A | CONTROLLING CALCIUM CONCENTRATION | ADIR ET COMPAGNIE (FR) | 1988-06-14 | — | — | US | disclosed |
| US-4727086-A | MODULATORS OF TRANSMEMBRANE AND INTRACELLULAR MOVEMENTS OF CALCIUM | ADIR ET COMPAGNIE (FR) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | CYP2D6 10/4885SLC6A2 1313/4885SLC6A4 1403/4885 |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | CYP2D6 567/4885SLC6A2 259/4885SLC6A4 99/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | CYP2D6 2808/4885SLC6A2 4151/4885SLC6A4 3416/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CYP2D6 238/4885SLC6A2 4658/4885SLC6A4 4305/4885 |
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | TRPM8, TAS2R8, TRPM7 | CYP2D6 3560/4885SLC6A2 4138/4885SLC6A4 4141/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | CYP2D6 1845/4885SLC6A2 3178/4885SLC6A4 2515/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | CYP2D6 4634/4885SLC6A2 4298/4885SLC6A4 4331/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | CYP2D6 2808/4885SLC6A2 4151/4885SLC6A4 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.